Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP278243.RA4d0-G8jRHDhF6BGni_5xPbEs63UVhzAjY6k13BIFmjQ130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP278243.RA4d0-G8jRHDhF6BGni_5xPbEs63UVhzAjY6k13BIFmjQ130_assertion type Assertion NP278243.RA4d0-G8jRHDhF6BGni_5xPbEs63UVhzAjY6k13BIFmjQ130_head.
- NP278243.RA4d0-G8jRHDhF6BGni_5xPbEs63UVhzAjY6k13BIFmjQ130_assertion description "[Inhibitors of the mammalian target of rapamycin (mTOR) are emerging as promising therapies for metastatic renal cell carcinoma (RCC).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP278243.RA4d0-G8jRHDhF6BGni_5xPbEs63UVhzAjY6k13BIFmjQ130_provenance.
- NP278243.RA4d0-G8jRHDhF6BGni_5xPbEs63UVhzAjY6k13BIFmjQ130_assertion evidence source_evidence_literature NP278243.RA4d0-G8jRHDhF6BGni_5xPbEs63UVhzAjY6k13BIFmjQ130_provenance.
- NP278243.RA4d0-G8jRHDhF6BGni_5xPbEs63UVhzAjY6k13BIFmjQ130_assertion SIO_000772 20830770 NP278243.RA4d0-G8jRHDhF6BGni_5xPbEs63UVhzAjY6k13BIFmjQ130_provenance.
- NP278243.RA4d0-G8jRHDhF6BGni_5xPbEs63UVhzAjY6k13BIFmjQ130_assertion wasDerivedFrom befree-20140225 NP278243.RA4d0-G8jRHDhF6BGni_5xPbEs63UVhzAjY6k13BIFmjQ130_provenance.
- NP278243.RA4d0-G8jRHDhF6BGni_5xPbEs63UVhzAjY6k13BIFmjQ130_assertion wasGeneratedBy ECO_0000203 NP278243.RA4d0-G8jRHDhF6BGni_5xPbEs63UVhzAjY6k13BIFmjQ130_provenance.